logo
31 million tons of supercharged seaweed is creeping toward beaches in Florida and around the Caribbean

31 million tons of supercharged seaweed is creeping toward beaches in Florida and around the Caribbean

Yahoo18-05-2025
The Atlantic Ocean has a toxic seaweed problem.
Floating in brown islands of algae, this year's sargassum bloom has already broken its own size record by millions of tons — and the growing season isn't done yet.
Now stretching across some 5,500 miles of ocean, the annual bloom is more than just an eyesore: Sargassum hurts ecosystems and economies wherever its overgrown arms reach. And they are spreading into Florida's waterways, coating marinas and beaches in the Miami area.
'Sargassum goes from being a very beneficial resource of the North Atlantic to becoming what we refer to as … a harmful algal bloom, when it comes ashore in excessive biomass,' said Brian LaPointe, a research professor at Florida Atlantic University's Harbor Branch Oceanographic Institute.
'What we have seen since 2011 are excessive inundation events all around the Caribbean region, the Gulf, as well as the South Florida region,' explained LaPointe, who has studied the seaweed for decades.
For more than a decade, Atlantic coastal communities have been inundated by more and more sargassum. Images of white sand beaches stretching into azure waters have been altered by the toxic and putrid invasion. In the water, it's home to larvae and other organisms that can irritate the skin of any passing swimmers.
As it rots on shore, it emits harmful gases— an infamous stench.
It's a blight on beaches that repels tourists during the high-travel season, ultimately hurting towns that rely on tourism to fuel their economy.
Rising ocean temperatures due to human-caused climate change have spurred this sargassum surplus, supercharging the seaweed. In April, the University of South Florida estimated this year's bloom is already at 31 million tons — '40% more' than the previous record from June 2022, according to LaPointe.
The sargassum bloom itself is not a new phenomenon. It's long provided a home to species from sea turtles to fish as winds and tides push it from the coast of West Africa toward Brazil, up into the Caribbean and the Gulf of Mexico.
'Sargassum has been around for eons. Colombus ran into it right in the Sargasso Sea,' La Pointe told CNN. 'But what we are seeing now is above and beyond what we had historically.'
Sargassum's growth is also being driven by an excess of nitrogen in the water, LaPointe said — and that's a key factor behind this year's monster bloom.
Some nitrogen may be coming from the atmosphere, carried in the air from the burning of fossil fuels or dust from the Sahara Desert.
But there's one major source: agricultural fertilizers. Used in the American heartland as well as in the Amazon basin where there's been rapid deforestation for farming, the nitrogen-rich fertilizers are likely making their way into the Mississippi and Amazon Rivers as runoff, which then carries it into the Atlantic.
And the Amazon basin has notched its lowest water levels on record amid two straight years of extreme drought — the worst since records began being kept in 1950.
'What happens when you have a severe drought in the world's largest watershed? You get all this organic matter that dries up. Plants dry up and die. And then, when the rain hits, what happens? All those nutrients wash out,' LaPointe hypothesized, adding that 'first flush' events like this are full of concentrations of nitrogen and phosphorus at peak levels, which go on to feed the bloom's growth explosion.
Unsurprisingly, the constant inundation of stinky, brown seaweed along the coast is not good for economies driven by tourism.
This year's bloom has already been making an appearance along Florida's east coast, from the Keys to Saint Augustine, according to reports on a sargassum monitoring site, and southeastern Florida could see more in the coming weeks. The unwanted algae has also been spotted in popular destinations from Mexico to Barbados and farther south.
'It's not good for the environment, because what you're smelling is hydrogen sulfide gas which is toxic,' LaPointe said.
In some places, the beaches are cleared of seaweed from sunrise to sunset — an expensive endeavor combing up sargassum that inundates the coastline with every wave. Some of the machinery used to clean the beaches adds its own pollution to the scenic environment, too.
'Resorts have gone out to their beaches with heavy equipment like front-end loaders, bulldozers, dump trucks to try to remove the sargassum to make those beaches available,' LaPointe said, as tourists don't want mounds of sargassum to mar their tropical views. 'The tourists check out, and they don't come back.'
This is a major tangle for places like Mexico's Yucatán Peninsula, which exists in the heart of the sargassum belt between the Gulf of Mexico and the Caribbean Sea.
The problem has become so pronounced along the Riviera Maya, Mara Lezama, the governor of Quintana Roo, a state in the peninsula, has taken to social media to say her state is working with the Mexican Navy to collect the seaweed in the water while also installing a nearly 6-mile barrier in the water to protect Quintana Roo's Mahahual, Playa del Carmen and Puerto Morelos beaches.
The barriers, which are similar to booms that contain oil spills, are just over a yard deep and are designed to keep the seaweed from reaching the coast.
As it approaches, the decaying sargassum can also create health problems for animals and humans.
'When it arrives to the coastal area, it creates a shadow from the sun, so everything that is below — all the life is not getting sunlight. So, it starts to affect the ecosystem, coastal ecosystem, and many things die,' said Christian Appendini, professor at the Universidad Nacional Autónoma de México.
'Then when it gets over the beach, it starts to decompose. And when it decomposes, it releases all the contaminants it has.'
Ammonia is another problem emitted by the decaying seaweed, LaPointe noted. The chemical compound 'strips the oxygen out of the waters along our coastal ecosystems like mangroves, coral reefs, seagrass beds,' he said.
'When you see the mass inundation events along the beaches, say in the Mexican Riviera, for example, you don't see many fish or crabs,' LaPointe continued. 'If you do, they're probably dead because there's no oxygen in that water.'
With sargassum cementing itself as an ongoing problem, some are looking into putting the seaweed to good use, instead.
Appendini says research is ongoing to find ways to use the sargassum for biofuel, building bricks, or as membranes for cleaning water, since it is particularly absorbent.
'They absorb all the heavy metals and contaminants in the water,' he told CNN. 'That's also why sargassum can be very toxic, because when it's drifting in the ocean it's just assimilating all the toxic elements in the ocean like cadmium, arsenic and other minerals and elements.'
There's also the possibility of carbon sequestration by sinking the excessive biomass to the bottom of the ocean. And there's interest in possibly using sargassum to replace one of the globe's other problems: plastic.
'If we could harvest this sargassum and produce this biodegradable product that could replace single use plastics, that would begin to restore the oceans regarding the serious plastic pollution that we're seeing,' LaPointe said.
As the sargassum situation remains pervasive for more than a decade now, Appendini said the record-breaking bloom should make the world pay attention.
'I think the sargassum blooms are like a warning that we need to be more mindful of how we are developing in this world,' Appendini said. 'We need to change … how we do things.'
CNN's Norma Galeana contributed to this story.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock
Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock

Yahoo

time5 hours ago

  • Yahoo

Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock

Miami, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ('ETST' or the 'Company'), a strategic holding company focused on acquiring and scaling high-potential businesses, today announced that its Board of Directors has approved a reduction of the Company's authorized shares of common stock from 350 million to 300 million. This strategic reduction in authorized shares of common stock is a direct reflection of the Board's confidence in the Company's current trajectory and its commitment to protecting long-term shareholder value. "This move by the Board of Directors aligns with our current goal of reducing the share count." said Giorgio R. Saumat, CEO of ETST. "It sends a clear signal to the investment community: we are confident in our financial health, strategic plan, and we are committed to preventing unnecessary shareholder dilution.' With the Company's outstanding share count at approximately 294.3 million, the Board determined that the previous authorization level of 350 million shares was no longer necessary given the Company's direction and financial planning. About Earth Science Tech, Inc. Earth Science Tech, Inc. operates as a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses. The Company's current operations include compounding pharmaceuticals, telemedicine and real estate development through its wholly owned subsidiaries: LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC ('Mister Meds'), and Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC., and an 80% interest in MagneChef. To learn more, please visit: LLC. based in Miami, Florida, is a fully licensed compounding pharmacy authorized to fulfill prescriptions in the following states and territories: Arizona, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Minnesota, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Rhode Island, Utah, Wisconsin and Puerto Rico. RxCompound is actively pursuing licensure in the remaining U.S. states. To learn more please visit: MisterMeds, LLC. Mister Meds, acquired on October 1, 2024, is in Abilene, Texas. The pharmacy received full compounding licensure in March 2025. It operates out of a 5,000 sq. ft. facility owned by Avenvi and includes advanced sterile compounding capabilities with both positive and negative pressure environments, as well as hazardous drug handling. Mister Meds is currently applying for licensure in states not yet serviced by RxCompound. To learn more please visit: Peaks Curative, LLC. Peaks is a telemedicine referral platform offering asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound and Mister Meds. The platform operates in states where either pharmacy is licensed. Through the development of its own healthcare provider network, and ongoing licensure expansion for both pharmacies, Peaks aims to offer services nationwide. In addition, the company has recently expanded into the veterinary market through the acquisition of To learn more please visit: Las Villas Health Care, Inc. Las Villas is a brick-and-mortar healthcare facility dedicated to the Spanish speaking community. Our expert-led services include advanced sexual health treatments, and customized solutions to enhance physical performance. We combine compassionate, personalized care with clear, trustworthy education—empowering you to take control of your health with confidence. To learn more please visit: LLC. Doconsultation was born with a passion to modernize the availability and delivery of home therapies. DOConsultations providers tailor a medication plan around your health and wellness goals and follow up with our patients to ensure results, while our partner pharmacies conveniently ship directly to your door. To learn more please visit: Avenvi, LLC. Avenvi is a diversified real estate company engaged in development, asset management, and financing. With a growing portfolio of real estate holdings, Avenvi provides turnkey solutions from development to end-user financing. It also manages investment activities for ETST and oversees the Company's ongoing $5 million share repurchase program. To learn more please visit: MagneChef MagneChef is a direct-to-consumer retail brand. Utilizing its patents and intellectual properties, the company aims to develop new products that can be marketed and sold online. Currently, the company has developed products for cooking. MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property. In addition, the company has recently expanded into the premium American-made BBQ tool brand market through the acquisition of BBQraft. To learn more please visit: About Earth Science Foundation, Inc. Earth Science Foundation Inc. a 501(c)(3) nonprofit organization incorporated on February 11, 2019, is the charitable arm of ETST. ESF accepts grants and donations to assist individuals who need financial support for prescription costs at both RxCompound and Mister Meds. SAFE HARBOR ACT: Forward-Looking Statements. Except for historical information, the matters discussed herein may be considered 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including, without limitation, future-oriented statements related to cash flow, gross margins, revenues, and expenses. These statements are based on and reflect our current expectations, estimates, assumptions and/or projections, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts. They may include forward-looking words such as 'expect,' 'expectation,' 'believe,' 'anticipate,' 'may,' 'could,' 'intend,' 'belief,' 'plan,' 'estimate,' 'target,' 'predict,' 'likely,' 'seek,' 'project,' 'model,' 'ongoing,' 'will,' 'should,' 'forecast,' 'outlook' or similar terminology. Forward-looking statements are subject to a number of risks and uncertainties that may cause the Company's actual results to differ materially from our intent, belief or current expectations, including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. Company Contact:Giorgio R. SaumatCEO and Chairman of the Board(305) 724-5684IR@

Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma

Yahoo

time7 hours ago

  • Yahoo

Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma

JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program. The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care. The STAR-GBM trial will assess the safety, tolerability, and pharmacokinetics of MT-125 in this patient population with significant unmet need. Exploratory endpoints include measures of efficacy, including progression-free survival and overall survival. The NCI SBIR program is one of the most competitive federal funding mechanisms for cancer-focused innovation, providing support to small businesses with technologies that have strong scientific merit, commercial potential, and a clear path to clinical impact. Bridge Awards, which require that matching funds from private capital be raised first, are reserved for companies with promising, later-stage projects that have already demonstrated significant technical progress and the potential to attract substantial private investment. "The NCI Bridge Award was perfectly timed to support our STAR-GBM trial, for which patient enrollment is set to begin in November," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics. "It will enable us to generate the data needed to position the program for later-stage development, potential partnerships, and future expansion into a wider range of patients. Our ultimate goal is to deliver a transformative treatment option for patients who currently face limited or inadequate therapeutic choices." About Myosin TherapeuticsMyosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins. For more information, visit Contact: contact@ View original content to download multimedia: SOURCE Myosin Therapeutics Inc.

NASA and SpaceX will launch a resupply mission to the ISS
NASA and SpaceX will launch a resupply mission to the ISS

Yahoo

time9 hours ago

  • Yahoo

NASA and SpaceX will launch a resupply mission to the ISS

NASA and SpaceX will launch the 33rd commercial resupply mission to the ISS from Cape Canaveral at 2:45 a.m. EDT on Sunday, August 24. The SpaceX Dragon spacecraft is scheduled to dock with the ISS on Monday, August 25, at 7:30 a.m. EDT, carrying more than 5,000 pounds of supplies and scientific experiments. Its objectives include delivering vital materials to the crew and performing experiments that could support future space missions and medical progress on Earth. Onboard science experiments include bone-forming stem cells to study bone loss prevention, materials for 3D-printed medical implants to improve nerve damage treatments, bioprinted liver tissue for blood vessel development in microgravity, and supplies for 3D printing metal cubes. The Dragon spacecraft will perform a reboost to maintain the ISS's altitude, using an independent propellant system to fuel two Draco engines with burns planned throughout Fall 2025. The Dragon spacecraft is expected to stay at the ISS until December, then return to Earth with research and cargo, landing in the Pacific Ocean off the coast of California. Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store